Logo image of EOLS

EVOLUS INC (EOLS) Stock Fundamental Analysis

USA - NASDAQ:EOLS - US30052C1071 - Common Stock

6.235 USD
-0.07 (-1.19%)
Last: 9/23/2025, 3:45:38 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to EOLS. EOLS was compared to 196 industry peers in the Pharmaceuticals industry. EOLS may be in some trouble as it scores bad on both profitability and health. EOLS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

EOLS had negative earnings in the past year.
EOLS had a negative operating cash flow in the past year.
EOLS had negative earnings in each of the past 5 years.
In the past 5 years EOLS always reported negative operating cash flow.
EOLS Yearly Net Income VS EBIT VS OCF VS FCFEOLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

EOLS's Return On Assets of -27.10% is in line compared to the rest of the industry. EOLS outperforms 54.59% of its industry peers.
Industry RankSector Rank
ROA -27.1%
ROE N/A
ROIC N/A
ROA(3y)-32.04%
ROA(5y)-38.45%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EOLS Yearly ROA, ROE, ROICEOLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600 -800

1.3 Margins

With a decent Gross Margin value of 66.63%, EOLS is doing good in the industry, outperforming 73.98% of the companies in the same industry.
EOLS's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for EOLS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 66.63%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.76%
GM growth 5Y-2.34%
EOLS Yearly Profit, Operating, Gross MarginsEOLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

3

2. Health

2.1 Basic Checks

EOLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, EOLS has more shares outstanding
EOLS has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, EOLS has an improved debt to assets ratio.
EOLS Yearly Shares OutstandingEOLS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
EOLS Yearly Total Debt VS Total AssetsEOLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

EOLS has an Altman-Z score of -1.91. This is a bad value and indicates that EOLS is not financially healthy and even has some risk of bankruptcy.
EOLS has a Altman-Z score (-1.91) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1.91
ROIC/WACCN/A
WACC11.2%
EOLS Yearly LT Debt VS Equity VS FCFEOLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

EOLS has a Current Ratio of 2.27. This indicates that EOLS is financially healthy and has no problem in meeting its short term obligations.
EOLS has a Current ratio of 2.27. This is comparable to the rest of the industry: EOLS outperforms 41.33% of its industry peers.
EOLS has a Quick Ratio of 1.86. This is a normal value and indicates that EOLS is financially healthy and should not expect problems in meeting its short term obligations.
EOLS's Quick ratio of 1.86 is in line compared to the rest of the industry. EOLS outperforms 43.88% of its industry peers.
Industry RankSector Rank
Current Ratio 2.27
Quick Ratio 1.86
EOLS Yearly Current Assets VS Current LiabilitesEOLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

6

3. Growth

3.1 Past

EOLS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -21.95%.
The Revenue has grown by 17.15% in the past year. This is quite good.
The Revenue has been growing by 50.14% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-21.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-475%
Revenue 1Y (TTM)17.15%
Revenue growth 3Y38.74%
Revenue growth 5Y50.14%
Sales Q2Q%3.7%

3.2 Future

EOLS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 62.30% yearly.
The Revenue is expected to grow by 22.28% on average over the next years. This is a very strong growth
EPS Next Y-96.86%
EPS Next 2Y85.81%
EPS Next 3Y82.31%
EPS Next 5Y62.3%
Revenue Next Year11.46%
Revenue Next 2Y19.42%
Revenue Next 3Y22.93%
Revenue Next 5Y22.28%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
EOLS Yearly Revenue VS EstimatesEOLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M
EOLS Yearly EPS VS EstimatesEOLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

EOLS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 17.17 indicates a rather expensive valuation of EOLS.
Compared to the rest of the industry, the Price/Forward Earnings ratio of EOLS indicates a somewhat cheap valuation: EOLS is cheaper than 78.06% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of EOLS to the average of the S&P500 Index (22.87), we can say EOLS is valued slightly cheaper.
Industry RankSector Rank
PE N/A
Fwd PE 17.17
EOLS Price Earnings VS Forward Price EarningsEOLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EOLS Per share dataEOLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3 4

4.3 Compensation for Growth

A more expensive valuation may be justified as EOLS's earnings are expected to grow with 82.31% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y85.81%
EPS Next 3Y82.31%

More info and screens

0

5. Dividend

5.1 Amount

EOLS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EVOLUS INC

NASDAQ:EOLS (9/23/2025, 3:45:38 PM)

6.235

-0.07 (-1.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-05 2025-08-05/amc
Earnings (Next)11-04 2025-11-04/amc
Inst Owners78.75%
Inst Owner Change6.75%
Ins Owners0.96%
Ins Owner Change0.12%
Market Cap403.34M
Analysts84.62
Price Target19.67 (215.48%)
Short Float %22.26%
Short Ratio8.13
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-54.87%
Min EPS beat(2)-108.79%
Max EPS beat(2)-0.95%
EPS beat(4)1
Avg EPS beat(4)-41.86%
Min EPS beat(4)-108.79%
Max EPS beat(4)3.2%
EPS beat(8)4
Avg EPS beat(8)-24.08%
EPS beat(12)8
Avg EPS beat(12)-14.96%
EPS beat(16)10
Avg EPS beat(16)-10.12%
Revenue beat(2)0
Avg Revenue beat(2)-12.02%
Min Revenue beat(2)-17.08%
Max Revenue beat(2)-6.96%
Revenue beat(4)0
Avg Revenue beat(4)-7.33%
Min Revenue beat(4)-17.08%
Max Revenue beat(4)-1.09%
Revenue beat(8)2
Avg Revenue beat(8)-2.45%
Revenue beat(12)4
Avg Revenue beat(12)-2.38%
Revenue beat(16)6
Avg Revenue beat(16)-1.12%
PT rev (1m)-16.15%
PT rev (3m)-16.15%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-350%
EPS NY rev (1m)0%
EPS NY rev (3m)-271.15%
Revenue NQ rev (1m)-0.21%
Revenue NQ rev (3m)-19.84%
Revenue NY rev (1m)-0.29%
Revenue NY rev (3m)-14.77%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 17.17
P/S 1.45
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.5
EYN/A
EPS(NY)0.36
Fwd EY5.82%
FCF(TTM)-0.75
FCFYN/A
OCF(TTM)-0.64
OCFYN/A
SpS4.3
BVpS-0.29
TBVpS-1.38
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.1%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 66.63%
FCFM N/A
ROA(3y)-32.04%
ROA(5y)-38.45%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.76%
GM growth 5Y-2.34%
F-Score2
Asset Turnover1.21
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 97.78%
Cap/Sales 2.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.27
Quick Ratio 1.86
Altman-Z -1.91
F-Score2
WACC11.2%
ROIC/WACCN/A
Cap/Depr(3y)62.29%
Cap/Depr(5y)49.76%
Cap/Sales(3y)1.53%
Cap/Sales(5y)2.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-21.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-475%
EPS Next Y-96.86%
EPS Next 2Y85.81%
EPS Next 3Y82.31%
EPS Next 5Y62.3%
Revenue 1Y (TTM)17.15%
Revenue growth 3Y38.74%
Revenue growth 5Y50.14%
Sales Q2Q%3.7%
Revenue Next Year11.46%
Revenue Next 2Y19.42%
Revenue Next 3Y22.93%
Revenue Next 5Y22.28%
EBIT growth 1Y-35.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year823.46%
EBIT Next 3Y320.78%
EBIT Next 5Y182.86%
FCF growth 1Y23.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.78%
OCF growth 3YN/A
OCF growth 5YN/A